Who
Matthew T. Wiley
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Definium Therapeutics; Chief Commercial Officer, BioXcel Therapeutics; Chief Commercial Officer, VYNE Therapeutics; Chief Commercial Officer, Foamix Pharmaceuticals.
In numbers
- Trades disclosed
- 59
- Buys
- 1
- Sells
- 6
- Bought
- $51K
- Sold
- $491K
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 3 Dec 2018
- Last trade
- 25 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 29 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $113K3,097 at $36.57 | filing |
| 25 Sep 2026filed 29 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $113K3,097 at $36.57 | filing |
| 14 Sep 2026filed 14 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 14 Sep 2026filed 14 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 12 Aug 2026filed 12 Aug 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 12 Aug 2026filed 12 Aug 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $129K2,867 at $45.03 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $129K2,867 at $45.03 | filing |
| 22 Jun 2026filed 22 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 17 Mar 2025filed 18 Mar 2025 | DFTX Definium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 3 Oct 2024filed 3 Oct 2024 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,4506,272 at $0.55 | filing |
| 17 Sep 2024filed 3 Oct 2024 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code A | —21,250 | filing |
| 16 Sep 2024filed 17 Sep 2024 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $148215 at $0.69 | filing |
| 15 Sep 2024filed 17 Sep 2024 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —750 at $0.00 | filing |
| 15 Sep 2024filed 17 Sep 2024 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —750 | filing |
| 22 Jul 2024filed 1 Apr 2025 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,875 at $0.00 | filing |
| 17 Jun 2024filed 18 Jun 2024 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $307244 at $1.26 | filing |
News
No headline names them, or the companies they trade most, lately.